^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL without del(17p)/TP53 mutation...Other recommended regimens...alemtuzumab ± rituximab